MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION
|
|
- Gervase West
- 5 years ago
- Views:
Transcription
1 MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION Chong-Kin LIAM Department of Medicine Faculty of Medicine University of Malaya Kuala Lumpur
2 COMMUNITY ACQUIRED PNEUMONIA A common disorder Annual incidence in USA - 12 per 1000 adults per 1000 in those aged >65 years Marfarlane J. Semin Respir Infect 1994; 9:153-65
3 COMMUNITY ACQUIRED PNEUMONIA In Japan Annual incidence: 15 per 1000 adults and children Annual incidence requiring hospitalisation: 3.4 per 1000 adults and children 6 th leading cause of death worldwide JRS guidelines (2005). Respirology 2006; 11:S79-S133
4 CAP: Key Bacterial Pathogens In most studies, Streptococcus pneumoniae is the most commonly identified pathogen followed by Haemophilus influenzae 40% S. pneumoniae H. influenzae 20% Bartlett JG, et al. Clin Infect Dis. 1998;26: ; Marrie TJ. Infect Dis Clin North Am. 1998;12: ; Reimer LG, Carroll KC. Clin Infect Dis.1998;26:
5 CAP: Key Bacterial Pathogens.. and atypical pathogens: Mycoplasma pneumoniae Chlamydophila pneumoniae and Legionella spp. S. pneumoniae H. influenzae 6% 40% Legionella spp. M. pneumoniae Atypical pathogens: 23% 10% 7% 20% C. pneumoniae Bartlett JG, et al. Clin Infect Dis. 1998;26: ; Marrie TJ. Infect Dis Clin North Am. 1998;12: ; Reimer LG, Carroll KC. Clin Infect Dis.1998;26:
6 CAP: Key Bacterial Pathogens Other bacteria include Moraxella catarrhalis, Staphylococcus aureus, Klebsiella spp., and other gram-negative bacilli 1% 16% S. pneumoniae H. influenzae 6% 40% Legionella spp. M. pneumoniae Atypical pathogens: 23% 10% 7% 20% C. pneumoniae M. catarrhalis Others Bartlett JG, et al. Clin Infect Dis. 1998;26: ; Marrie TJ. Infect Dis Clin North Am. 1998;12: ; Reimer LG, Carroll KC. Clin Infect Dis.1998;26:
7 Clinical Practice Guidelines Ambulatory patients Hospitalised patients (non-icu) Severe (ICU) CAP patients are generally categorised into 3 groups outpatients inpatients intensive care patients
8 IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72 Most common microbial aetiologies of CAP (in the West) Outpatient S. pneumoniae M. pneumoniae H. influenzae C. pneumoniae Respiratory viruses* Influenza A and B, adenovirus, RSV & parainfluenza Inpatient (non-icu) S. pneumoniae M. pneumoniae C. pneumoniae H. influenzae Legionella species Aspiration Respiratory viruses* For all 3 categories of patients, the number one pathogen is pneumococcus Inpatient (ICU) S. pneumoniae Staph. aureus Legionella spp. Enterobacteriaceae spp. Pseudomonas spp. H. Influenzae Ref: File TM. Community-acquired pneumonia. Lancet 2003; 362: [Based on collective data from recent studies]
9 IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72 Most common microbial aetiologies of CAP (in the West) Outpatient S. pneumoniae M. pneumoniae H. influenzae C. pneumoniae Respiratory viruses* Influenza A and B, adenovirus, RSV & parainfluenza Inpatient (non-icu) S. pneumoniae M. pneumoniae C. pneumoniae H. influenzae Legionella species Aspiration Respiratory viruses* For all 3 categories of patients, the number one pathogen is pneumococcus Atypical pathogens are also prominently represented Inpatient (ICU) S. pneumoniae Staph. aureus Legionella spp. Gram-negative bacilli H. Influenzae Legionella - an important pathogen in patients with severe CAP
10 Aetiologies of CAP Requiring Hospitalization in Asia 1 Location No. of patients Rank order / Frequency of microbial cause (%) Unknown Okayama 1 Ishida T, et al. Chest 1998;114: S pneumoniae 23 H influenzae 7 M pneumoniae 5 K pneumoniae 4 S milleri 4 39 Okayama 2 3 hospitals Miyashita N, et al. Chest 2000;119: S pneumoniae 21 H influenzae 11 M pneumoniae 10 C pneumoniae 8 S aureus 5 42 Korea 3 Woo JH, et al. Korean J Infect Dis 2001, 33: (588 cases) S pneumoniae 22 K pneumoniae 15 Ps aeruginosa 10 S aureus 10 S viridans 6 62 Hong Kong 4 CHS Chan, et al. Chest 1992;101: M tuberculosis 12 S pneumoniae 12 Chlamydia spp 6 Viral 6 H influenzae 4 59 The aetiology of CAP in Japan is quite similar to that of Western countries High incidence of infection by Gram ve bacilli Infection due to M tuberculosis may commonly present as CAP in countries with a high prevalence of TB
11 Aetiologies of CAP Requiring Hospitalization in Asia 2 Location Khon Kaen 5 Reechaipichitkul W, et al. Southeast Asian J Trop Med Public Health 2005; 36: Bangkok 5a 3 hospitals Wattanathum, et al. Chest 2003;123: Singapore 6 Hui KP, et al. Singapore Med J 1992;101:442-6 No. of patients Rank order / Frequency of microbial cause (%) Unknown S pneumoniae 11 S pneumoniae 22 M tuberculosis 21 B pseudomallei % in Bangkok 5a Gram -ve bacilli 18 (K. pneum 10) S pneumoniae 12 K pneumoniae 10 C. pneumoniae 16 Gram -ve bacilli 10 M pneumoniae 9 M pneumoniae 7 H influenzae 5 C pneumoniae 4 L pneumophila 5 29 M pneumoniae K. Lumpur 7 Liam CK, et al. Respirology 2001;6: K pneumoniae 10 S pneumoniae 6 H influenzae 6 M pneumoniae 4 Ps aeruginosa 4 58 Penang 8 Hooi LN, et al. Med J Malaysia 2001;56: M tuberculosis 15 K pneumoniae 7 Ps aeruginosa 6 S aureus 5 S pneumoniae Studies in Singapore and Malaysia (countries with a high prevalence of TB) also show pulmonary TB commonly presents as CAP 3 57
12 Aetiologies of CAP Requiring Hospitalization in Asia 3 Location Khon Kaen 5 Reechaipichitkul W, et al. Southeast Asian J Trop Med Public Health 2005; 36: Bangkok 5a 3 hospitals Wattanathum, et al. Chest 2003;123: Singapore 6 Hui KP, et al. Singapore Med J 1992;101:442-6 No. of patients Rank order / Frequency of microbial cause (%) Unknown S pneumoniae 11 S pneumoniae 22 M tuberculosis 21 B pseudomallei % in Bangkok 5a Gram -ve bacilli 18 (K. pneum 10) S pneumoniae 12 K pneumoniae 10 C. pneumoniae 16 Gram -ve bacilli 10 M pneumoniae 9 M pneumoniae 7 H influenzae 5 C pneumoniae 4 L pneumophila 5 29 M pneumoniae K. Lumpur 7 Liam CK, et al. Respirology 2001;6: K pneumoniae 10 S pneumoniae 6 H influenzae 6 M pneumoniae 4 Ps aeruginosa 4 58 K. Lumpur 9 Liam CK, et al. Respirology 2006;11: K pneumoniae 11 M pneumoniae 9 L pneumophila 6 M tuberculosis 5 S pneumoniae Studies in Singapore and Malaysia (countries with a high prevalence of TB) also show pulmonary TB commonly presents as CAP 4 53
13 Location Aetiologies of Severe CAP Requiring ICU Admission United Kingdom (4 studies) Other parts of Europe (10 studies) Singapore NUH Lee KH, Lee KH, et al. Singapore Med J 1996;37: Singapore SGH Tan YK, Tan YK, et al. Eur Respir J 1998;12: Khon Kaen Reechaipichitkul W, et al.southeast Asian J Trop Med Public Health 2004;35:430-3 No. of patients Rank order / Frequency of microbial cause (%) Unknown S pneumoniae 22 S pneumoniae 22 K pneumoniae 15 B pseudomallei 18 B pseudomallei 29 Legionella spp 18 Gram ve enteric bacilli 9 H influenzae 8 M tuberculosis 16 S pneumoniae 21 Patients who met ATS criteria for severe CAP Viruses 10 S aureus 7 S aureus 7 Klebsiella spp 9 K pneumoniae 19 S aureus 9 C pneumoniae 7 B pseudomallei 7 S aureus 9 H influenzae 12 Influenza A & B 5 32 Legionella spp 6 43 S pneumoniae 5 32 M pneumoniae 7 28 S aureus % of patients had co-morbidity, most common was diabetes mellitus; Mortality: 21%
14 Location Aetiologies of Severe CAP Requiring ICU Admission No. of patients Rank order / Frequency of microbial cause (%) Unknown S pneumoniae Legionella spp Viruses S aureus Influenza A Burkholderia pseudomallei should be considered a & B United Kingdom 185 (4 studies) causative 22 organism 18 in patients 10 with 9severe CAP 5 32 Other parts of Europe (10 studies) Singapore NUH Lee KH, Lee KH, et al. Singapore Med J 1996;37: Singapore SGH Tan YK, Tan YK, et al. Eur Respir J 1998;12: Khon Kaen Reechaipichitkul W, et al.southeast Asian J Trop Med Public Health 2004;35: S pneumoniae 22 K pneumoniae 15 B pseudomallei 18 in Gram Southeast ve S aureus Asia C pneumoniae enteric bacilli 9 H influenzae 8 M tuberculosis 16 7 S aureus 7 Klebsiella spp 9 7 B pseudomallei 7 S aureus 9 Legionella spp particularly if the patient has diabetes mellitus 105 B pseudomallei 29 S pneumoniae 21 K pneumoniae 19 H influenzae S pneumoniae 5 32 M pneumoniae 7 28 S aureus 6 41
15 Location Nova Scotia 1 Marrie TJ, et al. Am J Med 1996;101: Argentina Erard PH, et al. Am Soc Microbiol 1991;108:56A Lausanne Bochud PY, et al. Medicine 2001;80: Aetiologies of CAP treated on an ambulatory basis No. of patients Rank order / Frequency of microbial cause (%) Unknown M pneumoniae 23 S pneumoniae 13 S pneumoniae 23 C pneumoniae 11 M pneumoniae 7 M pneumoniae 14 M pneumoniae & C pneumoniae 3 C pneumoniae 4 Influenza virus 12 Influenza A 3 Influenza A 4 C pneumoniae 5 C burnetii 3 48 Cryptococcus spp 4 65 C burnetii 2 46 Finland Jokinen C, et al. Clin Infect Dis 2001;15: S pneumoniae 37 M pneumoniae 14 Chlamydiae 9 Viruses 8 H influenzae 4 45
16 Location Nova Scotia 1 Marrie TJ, et al. Am J Med 1996;101: Argentina Erard PH, et al. Am Soc Microbiol 1991;108:56A Lausanne Bochud PY, et al. Medicine 2001;80: Aetiologies of CAP treated on an ambulatory basis No. of patients Rank order / Frequency of microbial cause (%) Unknown M pneumoniae 23 S pneumoniae 13 S pneumoniae 23 C pneumoniae 11 M pneumoniae 7 M pneumoniae 14 M pneumoniae & C pneumoniae 3 C pneumoniae 4 Influenza virus 12 Influenza A 3 Influenza A 4 C pneumoniae 5 C burnetii 3 48 Cryptococcus spp 4 65 C burnetii 2 46 Finland Jokinen C, et al. Clin Infect Dis 2001;15: S pneumoniae 37 M pneumoniae 14 Chlamydiae 9 Viruses 8 H influenzae 4 45 Bangkok 3 hospitals Wattanathum, et al. Chest 2003;123: Japan 3 hospitals (Okayama) Miyashita N, et al. J Med Microbiol 2005; 54: C pneumoniae 37 M pneumoniae 27 M pneumoniae 30 S pneumoniae 12 S pneumoniae 13 C pneumoniae 11 L pneumophila 8 H influenzae 5 Mixed infection 13 Viruses 2 M catarrhalis
17 AsiA-CAP Study Ngeow YF, et al. Int J Infect Dis 2005 May;9: Results from 1374 patients with paired sera showed infection rates for Mycoplasma pneumoniae 12.2% Chlamydophila pneumoniae 4.7% Legionella pneumophila 6.6% Overall infection rate by atypical respiratory pathogens = 23.5%
18 Severity Assessment The key to deciding initial site of care Outpatient Medical ward Critical care ward / ICU Severity assessment is made on the basis of prognostic criteria: patients age comorbidities physical, laboratory and radiographic findings
19 Severity assessment & Prognostication Severity of illness score (e.g., CURB-65) Prognostic models (e.g., PSI) can be used to identify patients who may be treated as outpatients (Strong recommendation; level I evidence) IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
20 Severity Assessment Pneumonia Severity Index (PSI) Requires computation of a score based on 20 variables Fine MJ, et al. A prediction rule to identify low-risk patients with CAP. N Engl J Med 1997;336:243-50
21 Severity Assessment Pneumonia Severity Index (PSI) stratifies patients into 5 mortality risk classes: Risk Risk class Score 30-day mortality Low I No predictors 0.1% Low II < % Low III % Moderate IV % High V > % Fine MJ, et al. A prediction rule to identify low-risk patients with CAP. N Engl J Med 1997;336:243-50
22 Severity Assessment Pneumonia Severity Index (PSI) On the basis of associated mortality rates, patients in Risk class 30-day mortality I 0.1% II 0.6% III 0.9% IV 9.3% V 27.0% Treat as outpatients Treat in an observation unit or short hospitalisation Treat as inpatients Fine MJ, et al. A prediction rule to identify low-risk patients with CAP. N Engl J Med 1997;336:243-50
23 Severity Assessment CURB-65 score (6-point) adopted by BTS Score 1 point for each feature present Confusion Urea > 7 mmol/l Respiratory rate > 30/min Blood pressure (SBP < 90 mmhg or DBP < 60 mmhg) Age > 65 yrs Lim WS, et al. Thorax 2003;58:
24 CURB-65 score Risk of mortality Score 0 0.7% Score 1 3.2% Recommendations Patients who have a CURB-65 score of 0 or 1 are at low risk of death - can be treated as having non-severe pneumonia and may be suitable for home treatment Score 2 13% Score 3 17% Score % Score 5 57% At increased risk of death - should be considered for short stay inpatient treatment or hospital supervised outpatient treatment (use clinical judgement) Patients who have a CURB-65 score of 3 or more are at high risk of death and should be managed as severe pneumonia Lim WS, et al. Thorax 2003;58:
25 There is growing evidence that CURB, CURB-65 and CRB-65 all allow for similar predictions of death from CAP as compared to the PSI
26 A prospective observational study of 1016 consecutive inpatients with CAP in an Emergency Department mean (SD) age: 72 (+ 17) yrs The ability of the three rules to predict 30 day mortality was compared Yan Man S, et al. Prospective comparison of 3 predictive rules (PSI, CURB-65, CRB-65) for assessing severity of CAP (and to predict 30-day mortality) in Hong Kong. Thorax 2007; 62:
27 PSI class 30-day mortality (%) I 0 II 0.8 III 5 IV 9.3 V 22.1 CURB CRB All 3 predictive rules showed the same trend of increasing mortality with worsening risk groups (p <0.001) 4 40 Yan Man S, et al. Prospective comparison of 3 predictive rules for assessing severity of CAP in Hong Kong. Thorax 2007; 62:
28 Sensitivity, specificity, positive and negative predictive values of 30 day mortality of the different predictive rules All 3 clinical decision rules had high negative predictive values but low positive predictive values at all cut-off points and are therefore more useful in ruling out serious illness Yan Man S, et al. Prospective comparison of 3 predictive rules for assessing severity of CAP in Hong Kong. Thorax 2007; 62:
29 Sensitivity, specificity, positive and negative predictive values of 30 day mortality of the different predictive rules PSI : complicated computation of a score may not be practical for routine application in busy hospital emergency departments or primary care settings CURB-65 : simpler to apply CRB-65 : is also easily applicable in primary care settings All 3 clinical decision rules had high negative predictive values but low positive predictive values at all cut-off points and are therefore more useful in ruling out serious illness Yan Man S, et al. Prospective comparison of 3 predictive rules for assessing severity of CAP in Hong Kong. Thorax 2007; 62:
30 ICU admission rates also increased with the risk levels of each rule, but were only statistically significant in CURB-65 and CRB-65 Yan Man S, et al. Prospective comparison of 3 predictive rules for assessing severity of CAP in Hong Kong. Thorax 2007; 62:
31 Sensitivity and specificity for high-risk group of the 3 predictive rules in identifying ICU admission Sensitivity (%) Specificity (%) PSI CURB CRB Because of their low sensitivities, none of the 3 rules appears to be useful for identifying patients requiring ICU care Modified ATS rule Ewig S, et al. Severe CAP: assessment of severity criteria. Am J Respir Crit Care Med 1998;158: Yan Man S, et al. Prospective comparison of 3 predictive rules for assessing severity of CAP in Hong Kong. Thorax 2007; 62:
32 Sensitivity and specificity for high-risk group of the 3 predictive rules in identifying ICU admission Sensitivity (%) Specificity (%) PSI CURB CRB Although far from being perfect, the modified American Thoracic Society score is currently the best tool in identifying Because of their low sensitivities, none of the 3 rules appears to be useful for identifying patients requiring patients ICU for care ICU admission Modified ATS rule Ewig S, et al. Severe CAP: assessment of severity criteria. Am J Respir Crit Care Med 1998;158: Yan Man S, et al. Prospective comparison of 3 predictive rules for assessing severity of CAP in Hong Kong. Thorax 2007; 62:
33 Site-of-care decisions 1 Prediction rules give an indication of disease severity Prediction rules have not been found to be useful in predicting ICU admission Generally, patients of higher risk classes have higher rates of ICU admission Unlike 30 day mortality, the association is not strong enough to allow for individual predictions and decisions Criteria for ICU admission vary from country to country and from hospital to hospital Criteria for ICU admission: disease severity is not the only factor to consider; other factors to consider: disease prognosis, pre-morbid status, age of patient, and the availability of ICU resources
34 Site-of-care decisions 2 All predictive rules serve only as a guide to clinical management Severity of illness is not the only factor to be considered when deciding on admission Social and home circumstances must be considered as well Physicians should always exercise clinical judgment and common sense in making these decisions
35 Criteria for severe CAP Major criteria Need for mechanical ventilation Septic shock requiring vasopressors 2007 IDSA / ATS Consensus Guidelines
36 Criteria for severe CAP Major criteria Need for mechanical ventilation Septic shock requiring vasopressors Minor criteria Respiratory rate >30 breaths/min PaO 2 /FiO 2 ratio <250 Multilobar infiltrates Confusion/disorientation Uraemia (BUN level, >20 mg/dl) Leukopenia (WBC count, <4 x 10 9 /L) Thrombocytopenia (platelet count, <100 x 10 9 /L) Hypothermia (core temperature, <36ºC) Hypotension requiring aggressive fluid resuscitation 2007 IDSA / ATS Consensus Guidelines
37 ICU admission decision Direct admission to an ICU is required for patients with septic shock requiring vasopressors or with acute respiratory failure requiring intubation and mechanical ventilation (Strong recommendation; level II evidence) Direct admission to an ICU or high-level monitoring unit is recommended for patients with 3 of the minor criteria for severe CAP (Moderate recommendation; level II evidence) Mandell LA, et al. IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
38 ICU admission decision Direct admission to an ICU is required for patients with septic shock requiring vasopressors or with acute respiratory failure requiring intubation and mechanical ventilation (Strong recommendation; level II evidence) Direct admission to an ICU or high-level monitoring unit is recommended for patients with 3 of the minor criteria for severe CAP (Moderate recommendation; level II evidence) This recommendation requires prospective validation Mandell LA, et al. IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
39 Effects of antibiotic administration within 4 hrs of arrival at the hospital on in-hospital & 30-day mortality * OR:0.86 OR:0.62 Hosp Fine II-III Hospital IV-V 30 days Fine II- III OR: days Fine IV-V < 4h > 4 h *In Medicare patients older than 65 yrs who had not received pre-hospital antibiotic therapy (n = 13,771) Houck PM, et al. A retrospective study on Medicare patients. Arch Intern Med 2004;164:637 44
40 Effects of antibiotic administration within 4 hrs of arrival at the hospital on in-hospital & 30-day mortality * OR: % 18 reduction in both in-hospital and 30-day mortality OR:0.86 OR:0.62 Hosp Fine II-III Hospital IV-V 30 days Fine II- III 30 days Fine IV-V < 4h > 4 h *In Medicare patients older than 65 yrs who had not received pre-hospital antibiotic therapy (n = 13,771) Houck PM, et al. A retrospective study on Medicare patients. Arch Intern Med 2004;164:637 44
41 Treat early Initiation of antimicrobial therapy within 4 hrs of arrival at the hospital was associated with a 0.4 day shorter mean LOS Houck PM, et al. A retrospective study on Medicare patients. Arch Intern Med 2004; 164:637-44
42 Guidelines for managing CAP Principles of empirical therapy Treat early Initiation of antimicrobial therapy within 4 hrs of arrival at the hospital was associated with a 0.4 day shorter mean LOS Houck PM, et al. A retrospective study on Medicare patients. Arch Intern Med 2004; 164: In the 2003 IDSA guidelines (also JRS guidelines 2005), initiating antibiotic therapy within 4 hrs after registration for hospitalised patients was a performance indicator 2007 IDSA / ATS Consensus Guidelines: Rather than designating a specific window in which to initiate treatment, hospitalized patients with CAP should receive the first antibiotic dose in the ED
43 Guidelines for managing CAP Principles of empirical therapy Treat early Cannot reliably differentiate aetiology based on clinical and radiological findings
44 Guidelines for managing CAP Principles of empirical therapy Treat early Cannot reliably differentiate aetiology based on clinical and radiological findings Treat the most likely pathogens S. pneumoniae (?DRSP*); H. influenzae Atypicals Others (co-morbidity and local epidemiology)
45 Guidelines for managing CAP Principles of empirical therapy Treat early Cannot reliably differentiate aetiology based on clinical and radiological findings Treat the most likely pathogens S. pneumoniae (?DRSP*); H. influenzae Atypicals Others (co-morbidity and local epidemiology) Likely antibiotic sensitivity of presumed pathogens
46 Antibiotic Resistance Issues Resistance to commonly used antibiotics for CAP is major consideration in choosing empirical therapy Resistance patterns vary by geography Therefore, antibiotic recommendations must be modified based on local susceptibility patterns
47 Mandell Mandell LA, LA, et et al. al. IDSA IDSA // ATS ATS Consensus Consensus Guidelines. Guidelines. Clin ClinInfect Dis Dis2007; 44:S :S27-72 American American Thoracic Thoracic Society Society Guidelines Guidelines Am Am J J Respir RespirCrit CritCare Care Med Med2001; 163: : Risk factors for infection with -resistant Streptococcus pneumoniae Age <2 yrs or >65 yrs therapy within the previous 3 months Alcoholism Medical comorbidities Immunosuppressive illness or therapy Exposure to a child in a day care centre Probably related to greater exposure to antibiotics among these categories of individuals and increased selection of antibiotic-resistant strains Mandell LA, et al. IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
48 Risk factors for infection with -resistant Streptococcus pneumoniae Age <2 yrs or >65 yrs therapy within the previous 3 months Alcoholism Medical Recent treatment comorbidities with antimicrobials - the most significant: Immunosuppressive illness or therapy Exposure Recent therapy to a or child repeated in a courses day care of therapy centrewith s, macrolides,, or fluoroquinolones are risk factors for pneumococcal resistance to the same class of antibiotic Mandell LA, et al. IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
49 Prevalence of penicillin-resistant S. pneumoniae* in 12 Asian countries ( and ) 2001) Asian Network for Surveillance of Resistant Pathogens (ANSORP) China (Beijing, Shanghai) 9.8% 19.8% 0% 23.4% Vietnam 28.2% 20.6% Saudi Arabia 32.6% 71.4% NA 20.5% NA 10.3% India 3.8% 7.8% 0% 0% Thailand 35.7% 26.9% 22.2% 26.9% Penicillin-intermediate intermediate (MIC mg/l) Penicillin-resistant (MIC 2 mg/l) Malaysia 6.0% 9.1% 3.0% 29.5% Hong Kong NA 24.1% NA 43.8% South Korea 24.3% 9.7% 55.4% 54.8% * Clinical isolates Taiwan 9.3% 24.6% 29.4% 38.6% Philippines NA 27.3% NA 0% Singapore 4.9% 28.6 % 18.2 % 17.1% Song JH, et al. ANSORP. Antimicrob Agents Chemother June 2004; 48:2101-7
50 Prevalence of penicillin-resistant S. pneumoniae* in 12 Asian countries ( and ) 2001) Asian Network for Surveillance of Resistant Pathogens (ANSORP) China (Beijing, Shanghai) South Korea 9.8% 19.8% 24.3% 9.7% 0% 23.4% 55.4% 54.8% Vietnam 28.2% 20.6% Taiwan Saudi Arabia 32.6% 71.4% 9.3% 24.6% NA 20.5% Hong Kong 29.4% 38.6% NA 10.3% India NA 24.1% 3.8% 7.8% Philippines NA 43.8% 0% 0% NA 27.3% and 29.4% were penicillin-resistant NA 0% Thailand 35.7% 26.9% Singapore 22.2% 26.9% IDSA / ATS Consensus Guidelines on the management of CAP in adults. CID 4.9% 2007; :S27-72 % 18.2 % 17.1% The available data suggest that the clinically relevant level of Malaysia penicillin resistance 6.0% is 9.1% a MIC of at least 4 mg/l 3.0% 29.5% Penicillin-intermediate intermediate (MIC mg/l) Penicillin-resistant (MIC 2 mg/l) * Clinical isolates Overall, 23% of S pneumoniae isolates were penicillin-intermediate Feikin DR,, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, Am J Public Health 2000; 90: Song JH, et al. ANSORP. Antimicrob Agents Chemother June 2004; 48:2101-7
51 Prevalence of resistance of S. pneumoniae to other s and erythromycin in Asia Jan 2000 Jun 2001 China (Beijing, Shanghai) Co-amoxiclav 2.7%, 7.3% Cefuroxime 4.5%, 19.8% Ceftriaxone 0.0%, 1.1% Erythromycin 0.9%, 73.9% South Korea Co-amoxiclav 6.5%, 9.7% Cefuroxime 3.2%, 61.3% Ceftriaxone 3.2%, 3.2% Erythromycin 0.0%, 80.6% Jun 2001 ANSORP Taiwan Co-amoxiclav 3.5%, 1.8% Cefuroxime 8.8%, 40.4% Ceftriaxone 1.8%, 0.0% Erythromycin 1.8%, 86.0% Vietnam Co-amoxiclav 14.3%, 22.2% Cefuroxime 4.8%, 74.2% Ceftriaxone 9.5%, 3.2% Erythromycin 1.6%, 92.1% Hong Kong Co-amoxiclav 0.9%, 3.6% Cefuroxime 10.0%, 50.0% Ceftriaxone 3.7%, 0.0% Erythromycin 0.0%, 76.8% Intermediate Resistant Song JH, et al. ANSORP. Antimicrob Agents Chemother June 2004; 48:2101-7
52 Prevalence of resistance of S. pneumoniae to other s and erythromycin in Asia Jan 2000 Jun 2001 Jun 2001 ANSORP Saudi Arabia Co-amoxiclav 0.0%, 0.0% Cefuroxime 2.6%, 12.8% Ceftriaxone 0.0%, 0.0% Erythromycin 0.0%, 10.3% India Co-amoxiclav 0.0%, 0.0% Cefuroxime 0.0%, 1.3% Ceftriaxone 0.0%, 0.0% Erythromycin 0.0%, 1.3% Thailand Co-amoxiclav 0.0%, 0.0% Cefuroxime 1.9%, 36.5% Ceftriaxone 1.9%, 0.0% Erythromycin 5.8%, 36.5% Intermediate Resistant Malaysia Co-amoxiclav 2.3%, 0.0% Cefuroxime 2.3%, 29.5% Ceftriaxone 0.0%, 2.3% Erythromycin 6.8%, 34.1% Singapore Co-amoxiclav 0.0%, 0.0% Cefuroxime 5.7%, 28.6% Ceftriaxone 0.0%, 0.0% Erythromycin 2.9%, 40.0% Philippines Co-amoxiclav 0.0%, 0.0% Cefuroxime 0.0%, 0.0% Ceftriaxone 0.0%, 0.0% Erythromycin 4.5%, 18.2% Song JH, et al. ANSORP. Antimicrob Agents Chemother June 2004; 48:2101-7
53 Susceptibilities of S. pneumoniae isolates to fluoroquinolones in 11 Asian countries Jan 2000 Jan 2000 Jun 2001 China (Beijing, Shanghai) South Korea Taiwan Levofloxacin 0.0%, 0.0% Levofloxacin 0.0%, 0.0% Levofloxacin 0.0%, 1.8% Gatifloxacin 0.0%, 0.0% Gatifloxacin 0.0%, 0.0% Gatifloxacin 1.8%, 1.8% Moxifloxacin 0.0%, 0.0% Moxifloxacin 0.0%, 0.0% Moxifloxacin 1.8%, 0.0% Ciprofloxacin 3.6% Ciprofloxacin 6.5% Ciprofloxacin 7.0% Saudi Arabia India Hong Kong Levofloxacin 0.0%, 0.0% Levofloxacin 0.0%, 1.3% Levofloxacin 0.0%, 8.0% Gatifloxacin 0.0%, 0.0% Gatifloxacin 0.0%, 1.4% Gatifloxacin 0.9%, 8.3% Moxifloxacin 0.0%, 0.0% Moxifloxacin 1.3%, 0.0% Ciprofloxacin Moxifloxacin 6.3%, 1.8% 2.6% Ciprofloxacin 4.0% Ciprofloxacin 11.8% Thailand Vietnam Philippines Levofloxacin 0.0%, 0.0% Levofloxacin 0.0%, 0.0% Levofloxacin 0.0%, 0.0% Gatifloxacin 0.0%, 0.0% Gatifloxacin 0.0%, 0.0% Gatifloxacin 0.0%, 0.0% Moxifloxacin 0.0%, 0.0% Moxifloxacin 0.0%, 0.0% Moxifloxacin 0.0%, 0.0% Ciprofloxacin 3.8% Ciprofloxacin 4.8% Ciprofloxacin 9.1% Malaysia Singapore Levofloxacin 0.0%, 0.0% Levofloxacin 2.9%, 0.0% Gatifloxacin 0.0%, 0.0% Gatifloxacin 0.0%, 0.0% Moxifloxacin 0.0%, 0.0% Moxifloxacin 0.0%, 0.0% Intermediate Ciprofloxacin 4.6% Ciprofloxacin 5.9% Resistant Song JH, et al. ANSORP. Antimicrob Agents Chemother June 2004; 48:2101-7
54 Multi-drug resistant S pneumoniae classes of antibiotics) in 12 Asian countries Jan 2000 pneumoniae (i.e., resistance to at least 3 Jan 2000 Jun 2001 Overall rate of multi-drug resistant S pneumoniae was 26.8% MDR S pneumoniae : 71.4% of isolates from Vietnam 44.9% of isolates from Hong Kong 42.5% of isolates from Korea 30.9% of isolates from Taiwan Song JH, et al. ANSORP. Antimicrob Agents Chemother 2004; 48:2101-7
55 e of ce to e ed ished ses tive am.e., oses a e is a sted ccal vitro, es. Drug-resistant resistant S. pneumoniae (DRSP) The clinical relevance of DRSP for pneumonia is uncertain Current levels of resistance do not generally result in CAP treatment failures when appropriate agents (amoxicillin, ceftriaxone, or cefotaxime) and doses are used (even in bacteremia) There are data to suggest that resistance to macrolides and older FQs (ciprofloxacin and levofloxacin) results in clinical failure To date, no failures have been reported for the newer fluoroquinolones (moxifloxacin and gemifloxacin) Mandell LA, et al. IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
56 ERS, ATS 2001, IDSA 2003, IDSA/ATS 2007 algorithm for CAP CAP Outpatient treatment Inpatient treatment No cardiopulmonary disease History of cardiopulmonary disease Mild to moderate illness Severe CAP No modifiers +/- modifiers Risks for Ps aeruginosa No C/P disease No Modifier + C/P disease +/or Modifier Yes No
57 CAP: empirical antibiotic therapy IDSA/ATS 2007 Empirical antibiotic recommendations have not changed significantly from those of previous guidelines IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72
58 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Inpatient, non-icu Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [strong recommendation, level 1 evidence] or Doxycycline III [weak recommendation,, level 3 evidence] ICU Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
59 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I Inpatient, non-icu Comorbidities: chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressive drugs Use of antimicrobials within the previous 3 months: an alternative from a different class should be selected ICU Increase the likelihood of infection with DRSP and enteric gramnegative bacteria Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
60 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I Inpatient, non-icu ICU Moxifloxacin, gemifloxacin or levofloxacin [750 mg] High-dose amoxicillin 1 g 3 times daily, or high-dose amoxicillin-clavulanate 2 g 2 times daily or cefuroxime 500 mg 2 times daily Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
61 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I Inpatient, non-icu In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III [moderate recommendation, level 3 evidence] or + macrolide III [moderate recommendation, level 3 evidence] ICU
62 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ alone I or + macrolide I ICU The major discriminating factor between the 2 regimens is the patient s prior antibiotic exposure (within the past 3 months). Preferred s include cefotaxime, ceftriaxone, and ampicillin; ertapenem for selected patients Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
63 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ alone I or + macrolide I ICU Preferred s include cefotaxime, ceftriaxone, and ampicillin; ertapenem for selected patients Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
64 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ alone I or + macrolide I ICU Preferred s include cefotaxime, ceftriaxone, and ampicillin; ertapenem for selected patients Doxycycline is an alternative to the macrolide [level III evidence] Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
65 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ alone I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
66 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU For all patients admitted to the ICU, coverage for S. pneumoniae and Legionella species should be ensured by using a potent antipneumococcal and either a macrolide or a FQ Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
67 IDSA / ATS Consensus Guidelines on the management of CAP in adults. Clin Infect Dis 2007; 44:S27-72 Most common microbial aetiologies of CAP Outpatient S. pneumoniae M. pneumoniae H. influenzae C. pneumoniae Respiratory viruses Inpatient (non-icu) S. pneumoniae M. pneumoniae C. pneumoniae H. influenzae Legionella species Aspiration Respiratory viruses Inpatient (ICU) S. pneumoniae Legionella spp. H. Influenzae Enterobacteriaceae spp. Staph. aureus Pseudomonas spp. A review of 9 recent studies (that included 890 patients with CAP admitted to the ICU): the most common pathogens in the ICU population were (in descending order of frequency) S. pneumoniae, Legionella species, H. influenzae, Enterobacteriaceae species, S. aureus, and Pseudomonas species. The atypical pathogens collectively account for 20% of severe CAP episodes. The dominant atypical pathogen in severe CAP is Legionella. File TM. Community-acquired pneumonia. Lancet 2003; 362:
68 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU The recommended standard empirical regimen should routinely cover the 3 most common pathogens that cause severe CAP, all of the atypical pathogens, and most of the relevant Enterobacteriaceae species. Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
69 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I * cefotaxime, ceftraxone, ampicillin/sulbactam, ICU * + azithromycin II or * + respiratory FQ I Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
70 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU * + azithromycin II or * + respiratory FQ I For penicillin-allergic patients Respiratory FQ + aztreonam Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
71 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU * + azithromycin II or * + respiratory FQ I For penicillin-allergic patients Respiratory FQ + aztreonam If Pseudomonas is a consideration III Anti-pneumococcal pneumococcal,, anti- pseudomonal (piperacillin-tazobactam, cefepime, imipenem,, or meropenem) + either ciprofloxacin or levofloxacin (750 mg) or Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
72 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU * + azithromycin II or * + respiratory FQ I For penicillin-allergic patients Respiratory FQ + aztreonam If Pseudomonas is a consideration III Anti-pneumococcal pneumococcal,, anti- pseudomonal + aminoglycoside + azithromycin or Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
73 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU * + azithromycin II or * + respiratory FQ I For penicillin-allergic patients Respiratory FQ + aztreonam If Pseudomonas is a consideration III Anti-pneumococcal pneumococcal,, anti- pseudomonal + aminoglycoside + anti- pneumococcal FQ (for penicillin-allergic patients, substitute the with aztreonam) Mandell LA, et al. Clin Infect Dis 2007; 44:S27-72
74 IDSA/ATS Consensus Guidelines on the management of CAP in adults Site of treatment IDSA / ATS Guidelines 2007 Recommended empirical antibiotics for CAP Outpatient Previously healthy and no antimicrobial use within previous 3 mths Macrolide I [level 1 evidence] or Doxycycline III [level 3 evidence] Presence of comorbidities or antimicrobial use within previous 3 mths or other risks for DRSP infection Respiratory FQ I or + macrolide I In regions with high rate (>25%) of infection with high-level (MIC >16 µg/ml) macrolide-resistant S. pneumoniae Respiratory FQ III or + macrolide III Inpatient, non-icu Respiratory FQ I or + macrolide I For penicillin-allergic patients Respiratory FQ I ICU * + azithromycin II or * + respiratory FQ I For penicillin-allergic patients Respiratory FQ + aztreonam If Pseudomonas is a consideration III Anti-pneumococcal pneumococcal,, anti- pseudomonal + aminoglycoside + anti- pneumococcal FQ (for penicillin-allergic patients, substitute the with aztreonam) If CA-MRSA is a consideration Add vancomycin or linezolid III
75 2007 IDSA / ATS Consensus Guidelines Duration of antibiotic therapy Patients with CAP should be treated for a minimum of 5 days (level I evidence) Before discontinuation of therapy - should be afebrile for h - should have no more than 1 CAP-associated sign of clinical instability (level II evidence) Criteria for clinical stability Temperature <37.8C Heart rate < 100 /min Respiratory rate < 24 /min Systolic blood pressure >90 mm Hg Arterial oxygen saturation > 90% or po 2 > 60 mm Hg on room air Ability to maintain oral intake* Normal mental status*
76 Adjusted OR for 30-day all-cause mortality plotted against compliance with guideline-recommended antibiotics at Intermountain Healthcare hospitals Adjusted OR for 30-day all-cause mortality Circle area reflects the number of admissions per hospital The odds of mortality are 0.92 (p = 0.007) for each 10% increase in compliance Dean, N. C. et al. Chest 2006;130:
77 Any advantages in following guidelines? Reduction in hospital admission rate Shortens length of hospital stay (LOS) Reduction in in-hospital and 30-day mortality? Help control bacterial resistance in the community (minimise use of excessive antibiotics and improves accuracy of therapy) However, the impact of guidelines on resistance remains to be shown
78 THANK YOU
KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA
KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA Methodology: Expert opinion Issue Date: 8-97 Champion: Pulmonary Medicine Most Recent Update: 6-08, 7-10, 7-12 Key Stakeholders: Pulmonary Medicine,
More informationPneumonia Severity Scores:
Pneumonia Severity Scores: Are they Accurate Predictors of Mortality? JILL McEWEN, MD FRCPC Clinical Professor Department of Emergency Medicine University of British Columbia Vancouver, BC Canada President,
More informationThe IDSA/ATS consensus guidelines on the management of CAP in adults
The IDSA/ATS consensus guidelines on the management of CAP in adults F. Piffer F. Tardini R. Cosentini U.O. Medicina d'urgenza, Gruppo NIV, Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationCommunity-Acquired Pneumonia OBSOLETE 2
Community-Acquired Pneumonia OBSOLETE 2 Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with respect to appropriate
More informationPneumonia: The Forgotten Killer
Pneumonia: The Forgotten Killer David Glenn Weismiller, MD, ScM, FAAFP Department of Family and Community Medicine University of Nevada, Las Vegas School of Medicine Disclosure Statement It is the policy
More informationCharles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center
Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history
More informationPNEUMONIA. Patient Case: Chief Complaint: I have been short of breath and have been coughing up rust-colored phlegm for the past 3 days.
PNEUMONIA Relevant Guidelines: 2008 IDSA CAP guidelines: http://www.idsociety.org/guidelines/patient_care/idsa_practice_guidelines/infections_by_org an_system/lower/upper_respiratory/community-acquired_pneumonia_(cap)/
More informationCommunity-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. Community-Acquired Pneumonia Talk will focus on adults Guideline
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationThe Old Man s Friend (And the Ire of Many an ED QI Director) Objectives. Terminology 10/22/2009
Pneumonia Management & Chris Fee, MD Assistant Clinical Professor UCSF Department of Emergency Medicine The Old Man s Friend (And the Ire of Many an ED QI Director) 7th leading cause of death in US 915,000
More informationWORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation
Practical Pointers pointers For for Your your Practice practice The Multiple Facets of CAP Dr. George Fox, MD, MSc, FRCPC, FCCP Community acquired pneumonia (CAP) continues to be a significant health burden
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationCAP, HCAP, HAP, VAP. 1. In 1898, William Osler described community-acquired pneumonia as:
1. In 1898, William Osler described community-acquired pneumonia as: Brad Sharpe, M.D. Professor of Clinical Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu I have no relevant financial
More informationBradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF -- William Osler, M.D.
Bradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu a. An ailment that often leads to suffocation and death. b. A friend of the aged. c. A common
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationInfectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
SUPPLEMENT ARTICLE Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults Lionel A. Mandell, 1,a Richard G. Wunderink,
More informationPneumonia. Dr. Rami M Adil Al-Hayali Assistant professor in medicine
Pneumonia Dr. Rami M Adil Al-Hayali Assistant professor in medicine Definition Pneumonia is an acute respiratory illness caused by an infection of the lung parenchyma, associated with recently developed
More informationCommunity-acquired pneumonia in adults
Prim Care Clin Office Pract 30 (2003) 155 171 Community-acquired pneumonia in adults Julio A. Ramirez, MD a,b, * a Department of Medicine, University of Louisville School of Medicine, 512 S. Hancock Street,
More informationETIOLOGIES AND TREATMENT OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AT SRINAGARIND HOSPITAL, KHON KAEN, THAILAND
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH ETIOLOGIES AND TREATMENT OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AT SRINAGARIND HOSPITAL, KHON KAEN, THAILAND Wipa Reechaipichitkul
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationPOLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation
More informationSepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment
Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus
More informationSession: How to manage and prevent the different faces of pneumonia Severe CAP
Athens 19, 20 November 2015 Garyfallia Poulakou Consultant, Infectious Diseases 4 th Department of Internal Medicine, Attikon University Hospital of Athens Session: How to manage and prevent the different
More informationBrice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine
Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Discuss advances in predicting prognosis Understand dwhat we know (and don t know) about the Microbiology Recognize important
More informationObjectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children
Objectives Community-Acquired in infants and children Review of Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America - 2011 Sabah Charania,
More informationPneumonia in the Hospitalized
Pneumonia in the Hospitalized Patient: Use of Steroids Nicolette Myers, MD Pulmonary/Sleep/Critical Care November 9, 2018 Park Nicollet Clinic Facts About Pneumonia CAP is the 8 th most common cause of
More informationUpdate on resistance and epidemiology of CAP pathogens in Asia. Cao Bin, MD
Update on resistance and epidemiology of CAP pathogens in Asia Cao Bin, MD Dept Infectious Diseases and Clinical Microbiology Beijing Chaoyang Hospital, Capital Medical University Outlines Resistance trends
More informationFraser Health pandemic preparedness
Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE
More informationAdult CAP. How to approach for diagnosis. Natpatou Sanguanwongse, MD. Bureau of Emerging Infectious Disease July Sunday, July 8, 12
Adult CAP How to approach for diagnosis Natpatou Sanguanwongse, MD. Bureau of Emerging Infectious Disease July 2012 Community-acquired pneumonia (CAP) one of several disease in which individuals (who have
More informationCommunity Acquired Pneumonia-Adults Clinical Practice Guideline MedStar Health
Community Acquired Pneumonia-Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care of their patients.
More informationOutpatient Management of Patients With Community Acquired Pneumonia Clinical Practice Guideline September 2013
Clinical Practice Guideline September 2013 General Principles: Community Acquired Pneumonia (CAP), together with influenza, remains the seventh leading cause of death in the United States. According to
More informationCommunity Acquired Pneumonia. Background & Rationale to North American Guidelines. Lionel Mandell MD FRCPC Brussels Belgium
Community Acquired Pneumonia Background & Rationale to North American Guidelines Lionel Mandell MD FRCPC Brussels Belgium Consider Impact of the disease Issues to reflect upon Impact of the Disease 3-4
More informationHow do we define pneumonia?
Robert L. Keith MD FCCP Associate Professor of Medicine Division of Pulmonary Sciences & Critical Care Medicine Denver VA Medical Center University of Colorado Denver How do we define pneumonia? Fever
More informationCommunity Acquired Pneumonia. Abdullah Alharbi, MD, FCCP
Community Acquired Pneumonia Abdullah Alharbi, MD, FCCP A 68 y/ male presented to the ED with SOB and productive coughing for 2 days. Reports poor oral intake since onset due to nausea and intermittent
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationRepeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia
ORIGINAL ARTICLE Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia Chiung-Zuei Chen, 1 Po-Sheng Fan, 2 Chien-Chung
More informationCommunity Acquired Pneumonia in Adults Clinical Practice Guideline Antibiotic Stewardship
Community Acquired Pneumonia in Adults Clinical Practice Guideline Antibiotic Stewardship These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care
More informationCommunity Acquired Pneumonia: Measures to Improve Management and Healthcare Quality
Community Acquired Pneumonia: Measures to Improve Management and Healthcare Quality Gonzalo Bearman MD, MPH Assistant Professor of Internal Medicine Divisions of Quality Health Care & Infectious Diseases
More informationUpper...and Lower Respiratory Tract Infections
Upper...and Lower Respiratory Tract Infections Robin Jump, MD, PhD Cleveland Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University
More information10/2/2017. Pneumonia: Are We Missing the Mark? Objectives. Pneumonia
Pneumonia: Are We Missing the Mark? LaDawna Goering, DNP, APN, ANP-BC Nick Van Hise, Pharm. D, BCPS Objectives Diagnose Pneumonia Evaluate severity of illness tools and site of care decisions Review diagnostic
More informationDisclosures. Case 1. Acute Bronchitis. Acute Bronchitis. Community-Acquired Pneumonia and other Respiratory Tract Infections. What do you recommend?
Community-Acquired Pneumonia and other Respiratory Tract Infections none Disclosures Joel T. Katz, M.D. Associate Professor of Medicine Division of Infectious Diseases Brigham and Women s Hospital Case
More informationBradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF
Maximizing Care for Community- Acquired Pneumonia Bradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu 1. In 1898, William Osler described community-acquired
More informationAcute Respiratory Infection. Dr Anthony Gibson
Acute Respiratory Infection Dr Anthony Gibson Range of Conditions Upper tract Common Cold coryza Sore Throat- Pharyngitis Sinusitis Epiglottitis Range of Conditions Lower Acute Bronchitis Acute Exacerbation
More information27/11/2012. Parainfuenza 1, 2 3 Rhinovirus Coronavirus Adenovirus Respiratory syncytial virus (RSV) Chlamydophila pneumoniae Mycoplasma pneumonite
8 «Evidence-based Medicine-» 27/11/2012,,,, : :,,,,,,,, (30%-50%) () (5%-10%) (40%-50%) 20% Infuenza A B Parainfuenza 1, 2 3 Rhinovirus Coronavirus Adenovirus Respiratory syncytial virus (RSV) Chlamydophila
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationPNEUMONIA IN CHILDREN. IAP UG Teaching slides
PNEUMONIA IN CHILDREN 1 INTRODUCTION 156 million new episodes / yr. worldwide 151 million episodes developing world 95% in developing countries 19% of all deaths in children
More informationMAJOR ARTICLE. (See the editorial commentary by Mandell on pages 386 8)
MAJOR ARTICLE Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/ American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission Adamantia Liapikou,
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationAspiration pneumonia in older people
Aspiration pneumonia in older people Ayman Morish, M.D. Internal medicine, Critical care Medicine and Geriatrics Fellow. Contents Epidemiology Causes of aspiration pneumonia Issues of older age Management
More informationAn evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia
ORIGINAL ARTICLE EPIDEMIOLOGY An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia A. R. Akram 1, J. D. Chalmers 1, J. K. Taylor 2, J. Rutherford 2, A.
More informationTurkish Thoracic Society
Türk Toraks Derneği Turkish Thoracic Society Pocket Books Series Diagnosis and Treatment of Community Acquired Pneumonia in Children Short Version (Handbook) in English www.toraks.org.tr This report was
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationCharles Feldman. Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand
Opportunistic Infections Community Acquired Pneumonia Charles Feldman Professor of Pulmonology and Chief Physician Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand Introduction
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Mortality Risk and Etiologic Spectrum of Community-acquired Pneumonia in Hospitalized Adult Patients Cornelia TUDOSE, Assistant Professor of Pneumology;
More informationCommunity acquired pneumonia
Community acquired pneumonia definition Symptoms of an acute LRTI New focal signs on chest examination At least one systemic feature New radiographic shadow Defination{Crofton} IT IS A SYNDROME CAUSED
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
More informationK L Buising, K A Thursky, J F Black, L MacGregor, A C Street, M P Kennedy, G V Brown...
419 RESPIRATORY INFECTION A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia K L Buising, K A
More informationWright, Respiratory Infections in the Challenging Patient. Disclosures. Objectives
Respiratory Infections in the Challenging Patient Wendy L. Wright, MS, APRN, BC, FAANP, FAAN Adult / Family Nurse Practitioner Owner - Wright & Associates Family Healthcare Amherst, New Hampshire Owner
More informationSimplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data
ORIGINAL ARTICLE RESPIRATORY INFECTIONS Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data Waleed Salih, Stuart Schembri and James D. Chalmers Affiliations:
More informationMicrobial aetiology of community-acquired pneumonia and its relation to severity
< Additional data are published online only. To view these files please visit the journal online (http://thorax.bmj.com). 1 Servei de Pneumologia, Institut del Tòrax, Hospital Clinic, IDIBAPS, Universitat
More informationOnline Supplement for:
Online Supplement for: INFLUENCE OF COMBINED INTRAVENOUS AND TOPICAL ANTIBIOTIC PROPHYLAXIS ON THE INCIDENCE OF INFECTIONS, ORGAN DYSFUNCTIONS, AND MORTALITY IN CRITICALLY ILL SURGICAL PATIENTS A PROSPECTIVE,
More informationRespiratory Infections
Respiratory Infections NISHANT PRASAD, MD THE DR. JAMES J. RAHAL, JR. DIVISION OF INFECTIOUS DISEASES NEWYORK-PRESBYTERIAN QUEENS Disclosures Stockholder: Contrafect Corp., Bristol-Myers Squibb Co Research
More informationSupplementary Online Content
Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationThe Importance of Appropriate Treatment of Chronic Bronchitis
...CLINICIAN INTERVIEW... The Importance of Appropriate Treatment of Chronic Bronchitis An interview with Antonio Anzueto, MD, Associate Professor of Medicine, University of Texas Health Science Center,
More informationCommunity Acquired Pneumonia
April 2014 References: 1. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL Mace SE, McCracken Jr. GH, Moor MR, St. Peter SD, Stockwell JA, and Swanson JT. The Management of
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationPULMONARY EMERGENCIES
EMERGENCIES I. Pneumonia A. Bacterial Pneumonia (most common cause of a focal infiltrate) 1. Epidemiology a. Accounts for up to 10% of hospital admissions in the U.S. b. Most pneumonias are the result
More informationPneumococcal Pneumonia: Update on Therapy in the Era of Antibiotic Resistance
a of Antibiotic Resistance March 01, 2003 By Bernard Karnath, MD [1], Akua Agyeman, MD [2], and Albert Lai, MD [3] Sir William Osler once called pneumococcal pneumonia the captain of the men of death.
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationGetting Smart About: Upper Respiratory Infections
Getting Smart About: Upper Respiratory Infections Daniel Z. Uslan, MD Assistant Clinical Professor Director, Antimicrobial Stewardship Program UCLA Health System Disclosures None relevant to the topic
More informationClinical failure, community-acquired pneumonia, management, outcome, prognosis, risk-factors
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01535.x Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia M. Hoogewerf 1, J. J. Oosterheert 1, E. Hak 2, I. M.
More informationMETHODS. Resource utilization. Statistical analysis. Data collection. Lee JY, et al. Disease burden of pneumonia
ORIGINAL ARTICLE Korean J Intern Med 2014;29:764-773 Disease burden of pneumonia in Korean adults aged over 50 years stratified by age and underlying diseases Jung Yeon Lee 1, Chul Gyu Yoo 2, Hyo-Jin Kim
More informationThorax Online First, published on May 20, 2008 as /thx
Thorax Online First, published on May 20, 2008 as 10.1136/thx.2008.095562 Systolic Blood Pressure is Superior to Other Haemodynamic Predictors of Outcome in Community Acquired Pneumonia James D Chalmers
More informationPneumonia. Definition of pneumonia Infection of the lung parenchyma Usually bacterial
Pneumonia Definition of pneumonia Infection of the lung parenchyma Usually bacterial Epidemiology of pneumonia Commonest infectious cause of death in the UK and USA Incidence - 5-11 per 1000 per year Worse
More informationBackground. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
More informationPediatric Respiratory Infections
Pediatric Respiratory Infections Brenda Kelly PharmD BCPS Residency Program Director Virginia Mason Memorial, Yakima, Washington brendakelly@yvmh.org Disclosure The presenter has no actual or potential
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationDELL CHILDREN S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER. Community Acquired Pneumonia
DELL CHILDREN S MEDICAL CENTER Community Acquired Pneumonia LEGAL DISCLAIMER: The information provided by Dell Children s Medical Center of Texas (DCMCT), including but not limited to Clinical Pathways
More informationA Study of Prognosis and Outcome of Community Acquired Pneumonia in a Tertiary Care Centre
ISSN: 2319-7706 Volume 4 Number 8 (2015) pp. 763-769 http://www.ijcmas.com Original Research Article A Study of Prognosis and Outcome of Community Acquired Pneumonia in a Tertiary Care Centre Bhadra Reddy
More informationPneumococcal pneumonia
Pneumococcal pneumonia Wei Shen Lim Consultant Respiratory Physician & Honorary Professor of Medicine Nottingham University Hospitals NHS Trust University of Nottingham Declarations of interest Unrestricted
More informationCorticosteroids in Severe CAP. Mervyn Mer Department of Medicine & ICU Johannesburg Hospital University of the Witwatersrand
Corticosteroids in Severe CAP Mervyn Mer Department of Medicine & ICU Johannesburg Hospital University of the Witwatersrand Introduction Much controversy and debate regarding the use of corticosteroids
More informationCommunity-Acquired Bacterial Pneumonia: Is There Anything New? Steve Vacalis DO CaroMont Health Regional Medical Center Gastonia, North Carolina
Community-Acquired Bacterial Pneumonia: Is There Anything New? Steve Vacalis DO CaroMont Health Regional Medical Center Gastonia, North Carolina This presentation is sponsored by: and supported by an educational
More informationInvestigation and Management of Community-Acquired Pneumonia (CAP) Frequently Asked Questions
Investigation and Management of Community-Acquired Pneumonia (CAP) Frequently Asked Questions 1. Why was this algorithm developed? Emergency department physicians were seeking guidance about best antimicrobial
More informationClinical Practice Guidelines for Nursing- and Healthcareassociated Pneumonia (NHCAP) [Complete translation] $
respiratory investigation 51 (2013) 103 126 Contents lists available at SciVerse ScienceDirect Respiratory Investigation journal homepage: www.elsevier.com/locate/resinv Guideline Clinical Practice Guidelines
More informationHigh dose amoxicillin for sinusitis
High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationWeight of the IDSA/ATS minor criteria for severe community-acquired pneumonia *
Respiratory Medicine (2011) 105, 1543e1549 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Weight of the IDSA/ATS minor criteria for severe community-acquired pneumonia
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationInfluenza A (H1N1)pdm09 in Minnesota Epidemiology
Influenza A (H1N1)pdm09 in Minnesota Epidemiology Infectious Disease Epidemiology, Prevention and Control Division PO Box 64975 St. Paul, MN 55164-0975 Number of Influenza Hospitalizations by Influenza
More informationPreventing and Treating Community-Acquired Pneumonia
PL Detail-Document #310618 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2015 Preventing and Treating
More informationMDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationCatherine Casey S. Jones,
Community Acquired Pneumonia Catherine Casey S. Jones, PhD, RN, ANP-C, AE-C Catherine Casey S. Jones, PhD, RN, ANP-C, AE-C Texas Pulmonary & Critical Care Consultants, PA & Adjunct Professor at Texas Woman
More informationImportance of Atypical Pathogens of Community-Acquired Pneumonia
S35 Importance of Atypical Pathogens of Community-Acquired Pneumonia Joseph F. Plouffe Departments of Internal Medicine and Medical Microbiology and Immunology, Ohio State University College of Medicine,
More information